Resumen

CASAS-REZA, Pablo; GESTAL-VAZQUEZ, María; LOPEZ-LOPEZ, David  y  MATO-BUA, Rocío. Electroconvulsive therapy in neuroleptic malignant syndrome. Rev. mex. anestesiol. [online]. 2023, vol.46, n.2, pp.153-155.  Epub 28-Ago-2023. ISSN 0484-7903.  https://doi.org/10.35366/110206.

One of the most important adverse effects of neuroleptics is the possibility of triggering neuroleptic malignant syndrome (NMS). The diagnosis is determined by exclusion and the initial therapeutic management will be withdrawn by neuroleptics by the administration of benzodiazepines and, in extreme cases, the use of electroconvulsive therapy (ECT). ECT is an effective therapeutic option in these patients and in these cases a poor response to administration with antipsychotic drugs is obtained. Based on the case of the article «Rocuronium-sugammadex for the management of electroconvulsive therapy in neuroleptic malignant syndrome. A case report» where the successful management of the use of non-depolarizing relaxants and their specific reversal in electroconvulsive therapies in patients diagnosed with of malignant neuroleptic syndrome, we comment on the pathophysiology and anesthetic images as well as similarities with other hyperthermic entities, such as malignant hyperthermia.

Palabras llave : neuroleptic malignant syndrome; rocuronium-sugammadex; malignant hyperthermia electroconvulsive therapy.